A BILL 
To amend the Internal Revenue Code of 1986 to provide 
for extended expensing of pharmaceutical manufacturing 
property, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Make Medicine in 
4
America Again Act’’. 
5
SEC. 2. EXTENSION AND EXPANSION OF COST EXPENSING 
6
PROVISIONS FOR PHARMACEUTICAL MANU-
7
FACTURERS. 
8
(a) ALLOWANCE
OF BONUS DEPRECIATION
FOR 
9
PHARMACEUTICAL
MANUFACTURING
PROPERTY.—Sec-
10
21:03 Mar 22, 2022
H7166
2 
•HR 7166 IH
tion 168(k)(2)(A) of the Internal Revenue Code of 1986 
1
is amended— 
2
(1) in clause (i), by striking ‘‘or’’ in subclause 
3
(III), by striking ‘‘or’’ in subclause (IV), by adding 
4
‘‘or’’ at the end of subclause (V), and by adding at 
5
the end the following new subclause: 
6
‘‘(VI) which is pharmaceutical 
7
manufacturing property (as defined in 
8
paragraph 11).’’, and 
9
(2) in clause (iii), by striking the period and 
10
adding at the end ‘‘(other than pharmaceutical man-
11
ufacturing property).’’. 
12
(b) APPLICATION OF APPLICABLE PERCENTAGE.— 
13
Section 168(k)(6) of such Code is amended by adding at 
14
the end the following new subparagraph: 
15
‘‘(D) RULE FOR PHARMACEUTICAL MANU-
16
FACTURING
PROPERTY.—Notwithstanding any 
17
other provisions of this paragraph, in the case 
18
of any qualified property which is pharma-
19
ceutical manufacturing property, the term ‘ap-
20
plicable percentage’ means, in the case of prop-
21
erty placed in service after December 31, 2023, 
22
100 percent.’’. 
23
21:03 Mar 22, 2022
H7166
3 
•HR 7166 IH
(c) PHARMACEUTICAL MANUFACTURING PROPERTY 
1
DEFINED.—Section 168(k) of such Code is amended by 
2
adding at the end the following new paragraph: 
3
‘‘(11) 
PHARMACEUTICAL
MANUFACTURING 
4
PROPERTY
DEFINED.—For purposes of this sub-
5
section, the term ‘pharmaceutical manufacturing 
6
property’ means property, equipment, buildings, or 
7
facilities placed in service in the United States for 
8
the purpose of facilitating pharmaceutical manufac-
9
turing. 
10
‘‘(a) EFFECTIVE DATE.—The amendments made by 
11
this section shall apply to property placed in service after 
12
December 31, 2022.’’. 
13
SEC. 3. PHARMACEUTICAL MANUFACTURING CREDIT. 
14
(a) IN GENERAL.—Subpart D of part IV of sub-
15
chapter A of chapter 1 of the Internal Revenue Code of 
16
1986 is amended by adding at the end the following new 
17
section: 
18
‘‘SEC. 45U. PHARMACEUTICAL MANUFACTURING CREDIT. 
19
‘‘(a) IN GENERAL.—For purposes of section 38, the 
20
pharmaceutical manufacturing credit for the taxable year 
21
shall be an amount equal to 50 percent of the qualified 
22
production activity expenditures of the taxpayer for the 
23
taxable year. 
24
21:03 Mar 22, 2022
H7166
4 
•HR 7166 IH
‘‘(b) QUALIFIED PRODUCTION ACTIVITY EXPENDI-
1
TURES.—For purposes of this section— 
2
‘‘(1) IN GENERAL.—The term ‘qualified produc-
3
tion activity expenditures’ means— 
4
‘‘(A) wages paid or incurred to an em-
5
ployee of the taxpayer for services performed by 
6
such employee in the conduct of a qualified 
7
pharmaceutical manufacturing business in the 
8
United States (but only if the employee’s prin-
9
cipal place of employment is in the United 
10
States), 
11
‘‘(B) amounts paid or incurred for any 
12
tangible personal property (whether or not oth-
13
erwise properly chargeable to capital account) 
14
used in the conduct of a qualified pharma-
15
ceutical manufacturing business in the United 
16
States (but only if the primary use of such 
17
property is in the United States), and 
18
‘‘(C) any direct or indirect costs paid or in-
19
curred in the conduct of a qualified pharma-
20
ceutical manufacturing business in the United 
21
States. 
22
‘‘(2) QUALIFIED PHARMACEUTICAL MANUFAC-
23
TURING BUSINESS.— 
24
21:03 Mar 22, 2022
H7166
5 
•HR 7166 IH
‘‘(A) IN
GENERAL.—The term ‘qualified 
1
pharmaceutical manufacturing business’ means 
2
the trade or business of producing pharma-
3
ceuticals and active pharmaceutical ingredients. 
4
‘‘(B) ACTIVE
PHARMACEUTICAL
INGRE-
5
DIENT.—The term ‘active pharmaceutical ingre-
6
dients’ has the meaning given to such term in 
7
section 207.1 of title 21, Code of Federal Regu-
8
lations (and any successor regulations). 
9
‘‘(C) PHARMACEUTICAL.—The term ‘phar-
10
maceutical’— 
11
‘‘(i) means any drug (as defined in 
12
section 201 of the Federal Food, Drug, 
13
and Cosmetic Act), and 
14
‘‘(ii) includes a biological product (as 
15
defined in section 351 of the Public Health 
16
Service Act). 
17
‘‘(3) CERTAIN HEALTH PLAN EXPENSES TREAT-
18
ED AS WAGES.— 
19
‘‘(A) IN GENERAL.—For purposes of para-
20
graph (1), the term ‘wages’ shall include so 
21
much of the eligible employer’s qualified health 
22
plan expenses as are properly allocable to such 
23
wages. 
24
21:03 Mar 22, 2022
H7166
6 
•HR 7166 IH
‘‘(B) 
QUALIFIED
HEALTH
PLAN
EX-
1
PENSES.—For purposes of this paragraph, the 
2
term ‘qualified health plan expenses’ means 
3
amounts paid or incurred by the eligible em-
4
ployer to provide and maintain a group health 
5
plan (as defined in section 5000(b)(1)), but 
6
only to the extent that such amounts are ex-
7
cluded from the gross income of employees by 
8
reason of section 106(a) of such Code. 
9
‘‘(C) ALLOCATION RULES.—For purposes 
10
of this paragraph, qualified health plan ex-
11
penses shall be allocated to qualified wages in 
12
such manner as the Secretary may prescribe. 
13
Except as otherwise provided by the Secretary, 
14
such allocation shall be treated as properly 
15
made if made on the basis of being pro rata 
16
among employees and pro rata on the basis of 
17
periods of coverage (relative to the periods to 
18
which such wages relate). 
19
‘‘(4) UNITED
STATES.—The term ‘United 
20
States’ means the 50 States and the District of Co-
21
lumbia. 
22
‘‘(c) SPECIAL RULES.— 
23
‘‘(1) REDUCTION IN BASIS.—If a credit is de-
24
termined under this section with respect to any 
25
21:03 Mar 22, 2022
H7166
7 
•HR 7166 IH
property by reason of any qualified production activ-
1
ity expenditures described in subsection (b)(1)(B), 
2
the basis of such property shall be reduced by the 
3
amount of the credit so determined. 
4
‘‘(2) COORDINATION WITH OTHER CREDITS.— 
5
Any qualified production activity expenditures taken 
6
into account in determining the amount of the credit 
7
under subsection (a) shall not be taken into account 
8
in determining a credit under any other provision of 
9
this chapter. 
10
‘‘(3) LIMITATION ON WAGES TAKEN INTO AC-
11
COUNT.—The amount of wages taken into account 
12
under subsection (a) with respect to any employee 
13
shall not exceed an amount equal to the contribution 
14
and benefit base in effect under section 230 of the 
15
Social Security Act for the calendar year in which 
16
the taxable year begins.’’. 
17
(b) CREDIT ALLOWED AGAINST ALTERNATIVE MIN-
18
IMUM TAX.—Section 38(c)(4)(B) of such Code is amended 
19
by redesignating clauses (x), (xi), and (xii) as clauses (xi), 
20
(xii), and (xiii), respectively, and by inserting after clause 
21
(ix) the following new clause: 
22
‘‘(x) the credit determined under sec-
23
tion 45U,’’. 
24
23:37 Mar 22, 2022
H7166
8 
•HR 7166 IH
(c) DENIAL OF DEDUCTION.—Section 280C of such 
1
Code is amended by adding at the end the following new 
2
subsection: 
3
‘‘(i) PHARMACEUTICAL MANUFACTURING CREDIT.— 
4
No deduction shall be allowed for that portion of the quali-
5
fied production activity expenditures (as defined in section 
6
45U(b)) otherwise allowable as a deduction for the taxable 
7
year which is equal to the amount of the pharmaceutical 
8
manufacturing credit determined for such taxable year 
9
under section 45U(a).’’. 
10
(d) PART OF GENERAL BUSINESS CREDIT.—Section 
11
38(b) of such Code is amended by striking ‘‘plus’’ at the 
12
end of paragraph (32), by striking the period at the end 
13
of paragraph (33) and inserting ‘‘, plus’’, and by adding 
14
at the end the following new paragraph: 
15
‘‘(34) the pharmaceutical manufacturing credit 
16
determined under section 45U(a).’’. 
17
(e) CLERICAL AMENDMENT.—The table of sections 
18
for subpart D of part IV of subchapter A of chapter 1 
19
is amended by adding at the end the following new item: 
20
‘‘Sec. 45U. Pharmaceutical manufacturing credit.’’. 
(f) EFFECTIVE DATE.—The amendments made by 
21
this section shall apply to amounts paid or incurred after 
22
the date of the enactment of this Act. 
23
Æ 
21:03 Mar 22, 2022
H7166
